New York, Jan 14, 2026, 18:15 EST — After-hours
- Johnson & Johnson shares climbed in after-hours trading following new positive data on its Tecvayli blood-cancer treatment.
- The company reported that the late-stage study achieved key survival endpoints in patients with relapsed or refractory multiple myeloma.
- Next week, investors will zero in on Johnson & Johnson’s quarterly results, paying close attention to updates on its pipeline and ongoing litigation.
Johnson & Johnson shares climbed 2.3% to $218.55 in after-hours trading Wednesday following upbeat topline data from a late-stage multiple myeloma study for Tecvayli.
Investors are zeroing in on Johnson & Johnson’s drug pipeline for the next growth phase as the company gears up for its quarterly report next week. Oncology continues to drive momentum, with myeloma standing out as a competitive yet profitable segment.
The company reported that the Phase 3 MajesTEC-9 trial evaluated Tecvayli (teclistamab) alone versus standard treatments in patients previously treated with one to three therapy lines, including an anti-CD38 antibody and lenalidomide.
Johnson & Johnson reported that Tecvayli cut the risk of disease progression or death by 71% compared to standard care, and slashed the risk of death by 40% in a prespecified interim analysis. “TECVAYLI continues to break new ground,” said Yusri Elsayed, global therapeutic head of oncology at Johnson & Johnson Innovative Medicine. Roberto Mina from Emory University’s Winship Cancer Institute noted the results show “potential … to transform treatment earlier in the multiple myeloma journey.” JNJ.com
Progression-free survival measures how long patients live without their cancer worsening, while overall survival tracks the time until death. Johnson & Johnson revealed that an independent data monitoring committee has recommended unblinding the study. Full results are slated for presentation at a forthcoming major medical meeting and will be submitted to health authorities.
Teczvayli is a bispecific T-cell engager—an antibody engineered to latch onto two targets simultaneously, steering immune cells straight to cancer cells. In myeloma, Johnson & Johnson aims to advance these newer immune therapies into earlier treatment stages, rather than reserving them for late relapses.
Legal developments are shifting at the company. Delaware’s Supreme Court has overturned part of a $1 billion damages award linked to Johnson & Johnson’s 2019 Auris Health surgical-robotics acquisition. That decision could knock a few hundred million off the total when it’s recalculated. Johnson & Johnson said it is reviewing its options.
Johnson & Johnson stood out amid a broadly weaker market, closing higher while the S&P 500 slipped 0.5%.
Traders, however, remain stuck with the familiar disconnect between headline figures and the full data set. A closer examination of side effects, response durability, and the trial population’s makeup could shift the pace at which doctors embrace the regimen—and influence how payers approach reimbursement.
Johnson & Johnson’s Q4 earnings call is set for Jan. 21 at 8:30 a.m. ET. Investors will be watching closely for changes in guidance and fresh insights on the drug rollout pipeline. Attention will also focus on whether litigation updates make a comeback in the discussion.
